Form 4: Leap Therapeutics Insider Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Winklevoss Capital Fund, LLC and 4 others reported changes in beneficial ownership of Leap Therapeutics, Inc. common stock on October 12, 2026.

Summary

  • In-the-money derivative exercise: acquired 4,938,801 Common Stock at $0.00 ($4,939) on October 12, 2026; holds 29,793,414 after (Indirect).
  • In-the-money derivative exercise: disposed of 4,938,801 Pre-Funded Warrant (Right to Buy) at $0.52 ($2,566,201) on October 12, 2026; holds 97,229,007 after (Indirect).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Winklevoss Capital Fund, LLC — 10% owner

Winklevoss Treasury Investments, LLC — 10% owner

Tyler Howard Winklevoss — 10% owner

Cameron Howard Winklevoss — 10% owner

Winklevoss Capital Management, LLC — 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2026-10-12In-the-money derivative exerciseCommon Stock4,938,801$0$4.9K29,793,414
2026-10-12In-the-money derivative exercisePre-Funded Warrant (Right to Buy)4,938,801$1$2.6M97,229,007

Key Dates

DateDescription
2026-10-12In-the-money derivative exercise (4,938,801 shares)
2026-10-12In-the-money derivative exercise (4,938,801 shares)

Keywords

insider transaction, Form 4, CYPH, CYPHERPUNK TECHNOLOGIES INC., neutral, Winklevoss Capital Fund, LLC, Winklevoss Treasury Investments, LLC, Tyler Howard Winklevoss, Cameron Howard Winklevoss, Winklevoss Capital Management, LLC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.